NDA supported by results from a Phase II registration trial in China — — Second most common form of liver cancer after hepatocellular ...
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that it has submi...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immuno...
Following its recent clinical collaboration with the multinational pharmaceutical company BeOne Medicines to explore combination therapy with its markete...
Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and m...
T-MAXIMUM Pharmaceutical announced that its proprietary allogeneic, B7-H3-targeted CAR-T therapy, MT027, has received IND Clearance from the U.S. Food an...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance fr...
TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant...
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immuno...
Antengene Corporation Limited, a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing fir...
The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with stron...
Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announc...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced th...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced that its next-generation TRK inhibitor, zurletrectinib (ICP-72...
© 2026 Biopharma Boardroom. All Rights Reserved.
